Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Superoxide dismutase liposomal - Redoxe

Next Previous
Drug Profile

Superoxide dismutase liposomal - Redoxe

Alternative Names: APN-201; Liposomal recombinant human Cu/Zn-superoxide dismutase; Lipoxysan; rhSOD - Redoxe

Latest Information Update: 07 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polymun Scientific
  • Developer Apeiron Biologics; Polymun Scientific
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Oxidoreductases
  • Mechanism of Action Superoxide dismutase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Peyronie's disease; Radiodermatitis

Most Recent Events

  • 27 Jul 2015 No recent reports on development identified - Phase-II for Radiodermatitis (Prevention) in Austria (Topical)
  • 12 Mar 2013 Efficacy and adverse events data from a phase I/II trial in Radiodermatitis (Prevention) released by Apeiron Biologics
  • 23 Jan 2012 Apeiron Biologics initiates enrolment in a phase Ib/II trial for Radiodermatitis (Prevention) in Austria (NCT01513278)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top